| Intracellular redox state alters NMDA receptor response during aging through Ca2+/calmodulin-dependent protein kinase II K Bodhinathan, A Kumar, TC Foster Journal of Neuroscience 30 (5), 1914-1924, 2010 | 173 | 2010 |
| Susceptibility to calcium dysregulation during brain aging A Kumar, K Bodhinathan, TC Foster Frontiers in aging neuroscience 1, 907, 2009 | 126 | 2009 |
| Redox sensitive calcium stores underlie enhanced after hyperpolarization of aged neurons: role for ryanodine receptor mediated calcium signaling K Bodhinathan, A Kumar, TC Foster Journal of neurophysiology 104 (5), 2586-2593, 2010 | 87 | 2010 |
| Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome Z Zeier, A Kumar, K Bodhinathan, JA Feller, TC Foster, DC Bloom Gene therapy 16 (9), 1122-1129, 2009 | 79 | 2009 |
| α-Synuclein oligomers induce glutamate release from astrocytes and excessive extrasynaptic NMDAR activity in neurons, thus contributing to synapse loss D Trudler, S Sanz-Blasco, YS Eisele, S Ghatak, K Bodhinathan, ... Journal of Neuroscience 41 (10), 2264-2273, 2021 | 73 | 2021 |
| Molecular mechanism underlying ethanol activation of G-protein–gated inwardly rectifying potassium channels K Bodhinathan, PA Slesinger Proceedings of the National Academy of Sciences 110 (45), 18309-18314, 2013 | 63 | 2013 |
| Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease H Takahashi, P Xia, J Cui, M Talantova, K Bodhinathan, W Li, EA Holland, G ... Scientific Reports 5, 14781, 2015 | 61 | 2015 |
| Alcohol modulation of G-protein-gated inwardly rectifying potassium channels: from binding to therapeutics K Bodhinathan, PA Slesinger Frontiers in Physiology 5, 77785, 2014 | 44 | 2014 |
| Dynamic role of the tether helix in PIP2-dependent gating of a G protein–gated potassium channel E Lacin, P Aryal, IW Glaaser, K Bodhinathan, E Tsai, N Marsh, SJ Tucker, ... Journal of General Physiology 149 (8), 799-811, 2017 | 33 | 2017 |
| Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of rats: Impact on cognitive function, synaptic plasticity and pathology K Wu, S Li, K Bodhinathan, C Meyers, W Chen, M Campbell-Thompson, ... Neurobiology of learning and memory 97 (1), 69-80, 2012 | 31 | 2012 |
| Ras-association domain of sorting Nexin 27 is critical for regulating expression of GIRK potassium channels B Balana, L Bahima, K Bodhinathan, JJ Taura, NM Taylor, MY Nettleton, ... PloS one 8 (3), e59800, 2013 | 27 | 2013 |
| Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site D Dhar, K Mapa, R Pudi, P Srinivasan, K Bodhinathan, S Das Archives of virology 151, 509-524, 2006 | 21 | 2006 |
| Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for … LZ Ryerson, JF Foley, G Defer, JA Cohen, DL Arnold, H Butzkueven, ... Multiple Sclerosis and Related Disorders 72, 104561, 2023 | 5 | 2023 |
| Oxidative stress decreases NMDA receptor function in the hippocampus of aged animals K Bodhinathan, A Kumar, TC Foster 2007 Neuroscience Meeting Planner Online 256, 2007 | 5 | 2007 |
| Characterizing the ‘feel-good experience’in multiple sclerosis patients treated with natalizumab or other therapies J Foley, R Berkovich, M Gudesblatt, E Luce, B Schneider, C de Moor, ... Neurodegenerative Disease Management 13 (1), 23-34, 2023 | 4 | 2023 |
| Exploratory magnetic resonance imaging endpoints from NOVA: a randomized controlled study of the efficacy of 6-week dosing of natalizumab vs continued 4-week treatment for … DL Arnold, J Foley, G Defer, L Zhovtis-Ryerson, JA Cohen, H Butzkueven, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 370-371, 2022 | 3 | 2022 |
| Natalizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis Report Better" Feel-Good" Outcomes on Key Physical, Emotional, and Cognitive Domains Compared to Other … J Foley, R Berkovich, M Gudesblatt, C de Moor, S Licata, PR Ho, ... International Journal of MS Care 22, 2020 | 2 | 2020 |
| PML Incidence Rates in US Patients Treated With Natalizumab: Update From the TOUCH Program R Avila, B Adams, J Steverson, W Chin, L Dsilva, K Smirnakis, P Singhal, ... MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 101-101, 2022 | 1 | 2022 |
| Natalizumab reduces loss of gray matter and thalamic volume in patients with RRMS: Analysis from the AFFIRM trial K Nakamura, Z Sun, C Hara-Cleaver, R Avila, K Bodhinathan MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 130-131, 2022 | 1 | 2022 |
| MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide (P3-6.001) S Krieger, K Bodhinathan, Y Xu, H Miskin, L Lee, E Alvarez Neurology 102 (17_supplement_1), 6567, 2024 | | 2024 |
